N/A N=60 A New Approach for Controlling Hemostasis During Canal Treatment
Blood Contamination of Root Canal During Endodontic Therapy
Primary: Change From Baseline in Root Canal Bleeding — 3.40; 3.73; 0.26; 3.03 millimeters — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=166 Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers
Bleeding Peptic Ulcer
Primary: Number of Participants With Rebleeding — 3; 4 Participants
N/A N=26 Management of Persistent Epistaxis Using Floseal Hemostatic Matrix
Epistaxis
Primary: Number of Participants With Initial Hemostasis — 10; 11 Participants — p=1.000
N/A N=42 Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
N/A N=20 Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study
Bleeding Peptic Ulcers
Primary: Re-bleeding Within 4 Weeks — 3; 1 Participants
N/A N=20 Floseal Treatment for Posterior Epistaxis Study
Epistaxis
Primary: Effectiveness of Floseal for the Treatment of Posterior Epistaxis. — 20 participants
Phase 2 N=55 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Phase 4 N=1,034 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
Variceal Bleeding, Cirrhosis
Primary: 5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death) — 218; 216; 225 participants
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=101 EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Hemorrhage · Bleeding Hemorrhage
Primary: Number of Participants With Clinical Success: Cessation of Bleeding up to 24 Hours — 100 Participants
N/A N=56 Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 29.13 Bleeding events per year
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 4 N=72 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Heart Failure
Primary: Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant — 12; 15 Participants
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 3 N=253 TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Hemorrhage
Primary: Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes — 80.7; 50.0; 87.5; 44.4 percentage of participants — p=<0.001
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 4 N=48 DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
Dysfunctional Uterine Bleeding
Primary: Cessation of Bleeding Within 5 Days — 48 participants
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
Phase 3 N=764 A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Gastrointestinal Hemorrhage
Primary: Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo — 22; 40 Participants
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Phase 4 N=121 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Esophageal and Gastric Varices
Primary: Rebleeding From Gastric Varices — 14; 21 Participants
Phase 3 N=222 High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
N/A N=220 Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
Atrial Fibrillation
Primary: Percentage of Patients With Index Event Safety Outcomes (Ongoing/Resolved/Deceased) at Time of Hospital Discharge — 19.1; 76.8; 4.1 Percentage of participants
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
Phase 4 N=30 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Hemophilia A
Primary: Difference of Annualized Number of All Bleeds Between On-demand and Prophylaxis Period — 56.00 Bleeds
Phase 3 N=66 Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
Lung Transplant; Complications, Mechanical · Lung Transplant; Complications · Bleeding
Primary: Intra-procedural Hemorrhage Grading by the Performing Bronchoscopist — 4; 13; 11; 24 Procedures